目的 探討葛根素注射液聯(lián)合康柏西普眼用注射液治療非增殖期糖尿病視網(wǎng)膜病變的臨床療效。方法 選取2019年12月—2022年6月秦皇島市第二醫(yī)院收治的98例糖尿病視網(wǎng)膜病變患者，按照隨機(jī)數(shù)字表法將所有患者分為對照組和治療組，每組各49例。對照組使用康柏西普眼用注射液治療，在角膜緣4 mm處進(jìn)針4 mm，一次性緩慢注入康柏西普眼用注射液，每眼0.5 mg。治療組在對照組基礎(chǔ)上靜脈滴注葛根素注射液，400 mg/次，1次/d，10 d為1個(gè)療程，連續(xù)3個(gè)療程。兩組在治療30 d后統(tǒng)計(jì)療效。觀察兩組的臨床療效，比較兩組患者視力、眼部體征和血清指標(biāo)。結(jié)果 治療后，治療組的總有效率為87.76%，明顯高于對照組的總有效率71.43%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組的最佳矯正視力（BCVA）高于治療前（P＜0.05），且治療組的BCVA較對照組更高（P＜0.05）。治療后，兩組的黃斑中心凹厚度（CMT）、出血斑面積、視野灰度值低于治療前（P＜0.05）；治療后，治療組的CMT、出血斑面積、視野灰度值低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組的血清胱抑素C（Cys-C）、轉(zhuǎn)化生長因子-β₁（TGF-β₁）、同型半胱氨酸（Hcy）水平低于治療前（P＜0.05）；治療組的血清Cys-C、TGF-β₁、Hcy水平低于對照組，差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。結(jié)論 葛根素注射液聯(lián)合康柏西普眼用注射液治療糖尿病視網(wǎng)膜病變的療效確切，能改善患者視力，減輕眼部體征，降低血清Cys-C、TGF-β₁、Hcy水平，且安全性良好。

Objective To investigate the clinical efficacy of Puerarin Injection combined with Conbercept Ophthalmic Injection in treatment of non-proliferative diabetic retinopathy. Methods Patients (98 cases) with non-proliferative diabetic retinopathy in the Second Hospital of Qinhuangdao from December 2019 to June 2022 were divided into control and treatment groups according to the random number table method, and each group had 49 cases. Patients in the control group were given Conbercept Ophthalmic Injection, inject 4 mm at 4 mm of the corneal limbus, and slowly inject Conbercept Ophthalmic Injection once, 0.5 mg per eye. Patients in the treatment group were iv administered with Puerarin Injection on the basis of the control group, 400 mg/time, once daily, 10 days as a course of treatment, for 3 consecutive courses. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and visual acuity, ocular sign, serum indexes levels in two groups were compared. Results After treatment, the total effective rate of the treatment group was 87.76%, which was significantly higher than that of the control group (71.43%), with a statistically significant difference (P < 0.05). After treatment, the BCVA of two groups was higher than that before treatment (P < 0.05), and the BCVA of the treatment group was higher than that of the control group (P < 0.05). After treatment, the CMT, the area of bleeding spot, and the gray value of visual field in two groups were lower than those before treatment (P < 0.05). After treatment, the CMT, the area of bleeding spot, and the gray value of visual field in the treatment group were lower than those in the control group, with a statistically significant difference (P < 0.05). After treatment, the serum levels of Cys-C, TGF-β₁, and Hcy in two groups were lower than those before treatment (P < 0.05). The serum levels of Cys-C, TGF-β₁, and Hcy in the treatment group were lower than those in the control group (P < 0.05). Conclusion Puerarin Injection combined with Conbercept Ophthalmic Injection has clinical curative effect in treatment of non-proliferative diabetic retinopathy, can improve visual acuity, reduce the ocular sign, reduce the serum levels of Cys-C, TGF-β₁, and Hcy, with good safety.

R988.1

秦皇島市科學(xué)技術(shù)研究與發(fā)展計(jì)劃項(xiàng)目（201902A176）